Colistin for Nebulisation
|
|
- Bryan Atkins
- 7 years ago
- Views:
Transcription
1 Colistin for Nebulisation SCG: For the treatment of Pseudomonas aeruginosa lung infections AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE The following guidelines are designed to provide information relating to Colistin for nebulisation and to outline the responsibilities of the primary and secondary care teams in the prescribing of Colistin for nebulisation. Summary: Indication Eradication or long term prophylaxis for patients with Pseudomonas aeruginosa lung infection Dose Eradication: 1-2million units (MU) nebulised BD for 3 months Prophylaxis: 1-2 million units (MU) nebulised BD on a continuous or month on month off basis Dose and nebuliser system required will be communicated to GP and patient by secondary care clinician Other Ensure co-prescription of diluents: Water for injection or Sodium Chloride 0.9% volume between 1ml 4ml per dose, dependent on nebuliser system used. Introduction: Indication Treatment of Pseudomonas aeruginosa lung infections in patients with Cystic Fibrosis (CF) and patients with non CF Bronchiectasis. Pseudomonas aeruginosa is a pathogen that causes severe lung damage in patients Who become colonised and then chronically infected. Patients with Cystic Fibrosis and Bronchiectasis are at risk of significant morbidity and mortality from the damage caused by this pathogen. Nebulised antipseudomonal antibiotic treatment has been shown to improve lung function, slow the rate of respiratory decline and reduce the frequency of exacerbations of infection in these patients. Nebulised antibiotics are able to achieve high local concentrations with low systemic absorption and toxicity as opposed to intravenous antibiotics, where there is high risk of developing adverse effects from systemic absorption. EJ29 SHARED CARE GUIDELINE Colistin Page 1 of 6
2 RESPONSIBILITIES and ROLES Secondary Care Clinician Responsibilities: 1. To diagnose Pseudomonas aeruginosa infection in either CF patients or Bronchiectasis patients based on a timely and comprehensive assessment. 2. To initiate Colistin and ensure the first test dose is carried out before a continuous prescription is requested. 3. To supply the initial 28 days treatment. 4. To provide the nebuliser system and train the patient/carer in the use of the nebuliser and preparation of the medication. 5. To co-ordinate servicing/maintenance of the nebuliser system. 6. To monitor for response and adverse drug reactions (ADRs) during the first test dose and the initiation period. 7. To liaise with the general practitioner (GP) to share the patient s care when the test dose has been carried out and proven benefit has been established. 8. To outline to GP when therapy may be stopped assuming no improvement is recognised in the patient s condition. 9. To review the patients condition and efficacy of treatment 6 months after discharge from secondary care, and then annually thereafter, with consideration at each review as to whether treatment needs to continue. 10. To evaluate ADRs raised by the GP and evaluating any concerns arising from physical checks & reviews undertaken by GP. 11. To advise GP on related issues such as drug interactions etc. 12. To advise the GP on supply issues related to the prescribing of nebulised Colistin 13. In relation to eradication therapy, secondary care will supply the patient with sputum collection pots and advise the patient to send the specimens to their GP for processing in the laboratory. 14. The Consultant Physician will follow up results of the sputum cultures after the three months eradication therapy, and relay any information to the GP. 15. In relation to prophylactic therapy, advise the GP if the patient is on continuous treatment with Colistin or on an alternate month on month off basis. 16. To advise the GP if the patient should be prescribed generic Colistin or the Promixin brand of Colistin if it is deemed necessary to have medicine delivered via the I-neb nebulizer. GP Responsibilities: 1. To monitor the patient s overall health and well being. 2. To observe patient for evidence of ADRs or any abnormalities and raise with the secondary care clinician if necessary. 3. To prescribe Colistin after achievement of a stable dose regime by secondary care 4. To ensure advice is sought from the secondary care clinician if there is any significant change in the patient s physical health status. 5. To reduce and stop treatment in line with secondary care clinicians original request. 6. For eradication therapy, GP should ensure sputum samples from the patient are sent for processing two weeks after patient has completed the three month eradication therapy, and send any further samples for processing if requested to. Patient s role: 1. Report any adverse effects to their GP whilst using Colistin for nebulisation. 2. Ensure they have a clear understanding of their treatment. 3. Correctly store and administer the medicine. EJ29 SHARED CARE GUIDELINE Colistin Page 2 of 6
3 SPECIAL WARNING/ADVICE TO PATIENT Whilst on treatment, patients should continue with their standard treatments as clinically necessary. Where several different respiratory therapies are used, the following order is recommended: bronchodilator, Dornase alfa (Pulmozyme ) or Sodium Chloride 6% or 7% (Hypertonic Saline), chest physiotherapy, other inhaled medicines, and finally nebulised Colistin. BACK-UP ADVICE AND SUPPORT Papworth Hospital Main Switchboard Cystic Fibrosis Specialist Nurse ext: 4833 (bleep 446) Lung Defence specialist Nurse ext: 4079/4456 (bleep 685) Dr C Haworth ext: 4656 (bleep 363) Dr. H Barker ext: 4697 (bleep 142) Dr. D Wat ext: 4921 (bleep 864) Pharmacy advice: Pharmacy Medicines Information Service (For Healthcare Professional only) Fax: (direct line) (Mon-Fri 9am-5pm) Pharmacy Medicines Helpline (answer phone) (for patients only) (response to queries: Mon-Fri 9am- 5pm) Out of hours, contact the on-call pharmacist via switchboard. Consultant and medical staff are always available to give advice and can be contacted through the main hospital switchboard. SUPPORTING INFORMATION Indications Nebulised Colistin (Colomycin ) is indicated for chronic pulmonary Pseudomonas aeruginosa infection in Cystic fibrosis patients and patients diagnosed with bronchiectasis. It is also indicated for eradication of first pulmonary colonisation with Pseudomonas aeruginosa for a period of three weeks three months (initially with high dose ciprofloxacin). Dosage And Administration Adult Patients Eradication regime Cystic Fibrosis and Bronchiectasis patients: Colistin 1-2 million units nebulised twice daily for three months. Dose should be diluted in Water for injection or Sodium Chloride 0.9% to a volume of between 1ml 4ml dependant on brand and nebuliser system employed. Ciprofloxacin 750mg twice daily is co-administered for three months. EJ29 SHARED CARE GUIDELINE Colistin Page 3 of 6
4 Adult patients prophylaxis regime Cystic Fibrosis and Bronchiectasis patients: Colistin 1-2 million units nebulised twice daily. Dose should be diluted in Water for injection or Sodium Chloride 0.9% to a volume of between 1ml 4ml dependant on brand and nebuliser system employed. In some patients Colistin is used on an alternate month basis with other nebulised antipseudomal antibiotics eg. nebulised Tobramycin. If this regime is employed it will be communicated to the GP. Nebuliser systems Colistin can be administered through a wide variety of nebuliser systems. Papworth patients on Colomycin branded colistin will usually be using Pari Boy compressors coupled with Pari LC Plus nebuliser systems, or Portaneb compressors with Ventstream nebuliser kits, or Pari e-flow compressor-nebuliser systems. Promixin is exclusively nebulised via an I-neb hand-held nebuliser which is provided by the manufacturer. Ongoing use of the I-neb requires activation discs that are present in each pack of Promixin. Cautions / Contraindications Colistin is contra-indicated in patients with a hypersensitivity to Colistin (colistin / colomycin) or polymyxin B. Contra-indicated in patients with myasthenia gravis. Should be used with extreme caution in patients with porphyria. Colistin crosses the placental barrier and there may be a risk of foetal toxicity if repeated doses are given to pregnant patients. Exposure to pregnant carers during nebulisation should be minimised. Advising patients and carers is the responsibility of the specialist service. Colistin is excreted in breast milk. Use in pregnant or breast-feeding mothers should only proceed if the benefit to the mother outweighs the potential risk to the foetus and infant. Each patient will be individually assessed and informed whether or not to continue treatment. Therapeutic Use Used in the long-term treatment of chronic Ps. aeruginosa infection or also used as part of an eradication regime to treat new Ps. aeruginosa colonisation. Adverse Effects Transpulmonary absorption of Colistin is generally considered to be negligible therefore there is a low risk of systemic toxicity. Nebulised Colistin causes bronchoconstriction in some patients which may lead to discontinuation. This may be relieved in some patients by using an inhaled bronchodilator prior to nebulisation. A full list of undesirable effects, recorded from post-marketing data is available from the Summary of Product Characteristics which can be found at EJ29 SHARED CARE GUIDELINE Colistin Page 4 of 6
5 Monitoring Regular monitoring during treatment is essential to detect adverse reactions at an early stage and patients should be counselled about the risk factors and to report all signs and symptoms of toxicity. Through the hospital consultant, regular sputum samples / respiratory function monitoring will take place. Drug Interactions There are no recorded drug interactions when using the nebulised route as transpulmonary absorption of Colistin is generally considered to be negligible. Cost BNF list price (61 st edition) for Colistin (Colomycin ) 2 Million units (2MU) is 3.09 (ex VAT) BNF list price (61 st edition) for Colistin (Promixin ) 1 Million units (1MU) is 4.60 (ex VAT) Therefore: For 3 months of eradication therapy the cost is: (ex VAT) (Colomycin ) For Long term prophylaxis taken on a continuous basis for 12 months, the yearly cost for 2 million units twice daily is : (ex VAT) (Colomycin ) ( nebuliser consumables) (ex VAT) (Promixin ) For 6 months of therapy (when taken in an alternate month basis for long term prophylaxis) the yearly cost is: (ex VAT) (Colistin ) ( nebuliser consumables) 1656 (ex VAT) (Promixin ) Availability Colistin (Colomycin ) 1 million and 2 million unit injections may be obtained on prescription via community pharmacies. Colistin (Promixin ) 1 million units is also available for nebulisation which is delivered exclusively via the I-neb nebuliser device. 1 million units delivered in this way is equivalent to 2 million units of conventional Colistin delivered via other nebulisers. Before nebulising a dose of Colistin, the patient should either inhale or nebulise a dose of a bronchodilator. Each vial of Colistin (Colomycin ) should then be reconstituted with water for injections or sodium chloride 0.9% to an appropriate volume for nebulisation (usually 1 4mls dependent on dose and nebuliser device) References 1. Forest Laboratories UK Ltd Colomycin injection Summary of Product Characteristics. Last updated December 2009 (available from emc website ( accessed 06/09/ Profile Pharma Ltd Promixin injection Summary of Product Characteristics. Last updated 15 th June 2011 (available from emc website ( accessed 21/09/11. EJ29 SHARED CARE GUIDELINE Colistin Page 5 of 6
6 3. Joint Formulary Committee for the British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). 61st ed. London: BMJ Publishing / RPS Publishing. March Guidelines: Prepared by: Clare Cox - Cystic Fibrosis Pharmacist and Duncan Grady - Thoracic Directorate Pharmacist in consultation with Dr Haworth 06/2011. Approved by: Thoracic Specialty Management Group: 09/2011 Approved by: Drugs and Therapeutics Committee, Papworth Hospital NHS Foundation Trust, Chairman s action: 03/11/2011. EJ29 SHARED CARE GUIDELINE Colistin Page 6 of 6
Humulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationPulsating Aerosol. The New Wave in SINUSitis Therapy. Cystic Fibrosis. Focus on. For the precise, effective and gentle treatment of sinusitis
The New Wave in SINUSitis Therapy Focus on Cystic Fibrosis Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases
More informationPlease see the NHS Surrey Nebulised Treatment Pathway attached below.
Surrey Primary Care Trust Cedar Court Guildford Road Leatherhead KT22 9AE Tel: 01372 201700 Fax: 01372 201706 www.surreyhealth.nhs.uk November 11 th 2010 To: NHS Surrey GP s and Walk in Centre staff Re:
More informationDeveloped / Reviewed by the Collaborative Provider PGD (Patient Group Direction) Group (CPPGDG) and approved by the following members of the CPPGDG:
Patient Group Direction 7.02 version 4.0 Administration of Intravenous Adrenaline (Epinephrine) 1 in 10,000 (100micrograms per ml) Injection in Cardiopulmonary by Registered Practitioners in Torbay and
More informationNational Patient Safety Agency. Risk Assessment of Injectable Medicines. STEP 1 Local Risk Factor Assessment. STEP 2 Product Risk Factor Assessment
NPSA Injectable Medicines Risk Assessment Tool National Patient Safety Agency Risk Assessment of Injectable Medicines STEP 1 Local Risk Factor Assessment. Carry out a baseline assessment in a near patient
More informationPharmacists improving care in care homes
The Royal Pharmaceutical Society believes that better utilisation of pharmacists skills in care homes will bring significant benefits to care home residents, care homes providers and the NHS. Introduction
More information2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements
Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their
More informationCommunity health care services Alternatives to acute admission & Facilitated discharge options. Directory
Community health care services Alternatives to acute admission & Facilitated discharge options Directory Introduction The purpose of this directory is to provide primary and secondary health and social
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationSAMPLE ANTIMICROBIAL STEWARDSHIP POLICY
SAMPLE ANTIMICROBIAL STEWARDSHIP POLICY FOR A LOCAL HEALTH DISTRICT OR NETWORK Purpose of this document The development of an official policy for Antimicrobial Stewardship (AMS) is a fundamental step towards
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationNational Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of
More informationPregnancy and Tuberculosis. Information for clinicians
Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB
More informationLothian Guideline for Domiciliary Oxygen Therapy Service for COPD
Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD This document describes the standard for clinical assessment, prescription, optimal management and follow-up of patients receiving domiciliary
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationTopical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement
Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationBriefing for Doctors. Introduction. Electronic Prescribing. Electronic Prescribing:
Electronic Prescribing: Briefing for Doctors Electronic Prescribing Introduction Electronic prescribing (eprescribing) systems can help improve the safety and efficiency of healthcare by aiding the choice,
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationNote that the following document is copyright, details of which are provided on the next page.
Please note that the following document was created by the former Australian Council for Safety and Quality in Health Care. The former Council ceased its activities on 31 December 2005 and the Australian
More informationVersion 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality A Guideline for the Management of Acute Alcohol Withdrawal
More informationGUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
More informationMedication Management Guidelines for Nurses and Midwives
Medication Management Guidelines for Nurses and Midwives 1. Introduction As the statutory body responsible for the regulation of nursing and midwifery practice in Western Australia (WA), the Nurses & Midwives
More informationPRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY
PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY Prepared by: NPSA Anticoagulation Steering Group Approved by: Wirral Drug & Therapeutics Committee 14 th May 2008 Review:
More informationPG Certificate / PG Diploma / MSc in Clinical Pharmacy
PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme
More informationGUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS
GUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS 5 th Edition November 2015 NHS Pharmaceutical Quality Assurance Committee 2015 British Oncology Pharmacists Association Pharmaceutical
More informationZOVIRAX Cold Sore Cream
Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationhealthcare associated infection 1.2
healthcare associated infection A C T I O N G U I D E 1.2 AUSTRALIAN SAFETY AND QUALITY GOALS FOR HEALTH CARE What are the goals? The Australian Safety and Quality Goals for Health Care set out some important
More informationCYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE
CYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE 1. Cystic fibrosis introduction 2. CF Foundation centers 3. Care disciplines: physician specialists (pulmonary, GI, endocrine, genetics, palliative
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationPROMIXIN, POWDER FOR NEBULISER SOLUTION
PROMIXIN, POWDER FOR NEBULISER SOLUTION Colistimethate Sodium Ph Eur UK/H/0618/01/E01 Applicant: Profile Pharma Limited LAY SUMMARY On 21 March 2010, Austria, France, the Netherlands, Norway, Poland, Portugal
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationUse of medicines outside of their UK marketing authorisation in pain management and palliative medicine
The British Pain Society Use of medicines outside of their UK marketing authorisation in pain management and palliative medicine This is a consensus document prepared on behalf of the British Pain Society
More informationGuideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
More informationBeaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject
Beaumont Hospital Department of Nephrology and Renal Nursing Guideline Name: Guideline for administering Ferinject Guideline Number: 18 Guideline Version: a Developed By: Louise Kelly CNM 1 Renal Day Care
More informationAll Wales Prescription Writing Standards
All Wales Prescription Writing Standards These standards should be read in conjunction with completing the All Wales Medication Chart e- learning package, available on the Learning@NHSWales internet site
More informationSalbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036
Salbutamol 1mg/ml Nebuliser Solution Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationAdministrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
More informationGuidance on adverse drug reactions
Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system
More informationPLAN OF ACTION FOR. Physician Name Signature License Date
PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes
More informationMedicare C/D Medical Coverage Policy
Nebulizer Medications Origination: June 17, 2009 Review Date: October 21, 2015 Next Review: October, 2017 Medicare C/D Medical Coverage Policy DESCRIPTION Nebulizer medications are used to prevent and
More informationTechnology appraisal guidance Published: 27 March 2013 nice.org.uk/guidance/ta276. NICE 2013. All rights reserved.
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis Technology appraisal guidance Published: 27 March 2013 nice.org.uk/guidance/ta276
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More informationUniversity of Nebraska Prescription Drug Program 2014
University of Nebraska Prescription Drug Program 2014 The University of Nebraska s prescription benefit program is administered by CVS Caremark, a leading national provider of prescription drug benefit
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March 2007. Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 4 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationPOLICY FOR MANAGING THE BOUNDARIES OF NHS AND PRIVATE FUNDED HEALTHCARE DOCUMENT CONTROL
POLICY FOR MANAGING THE BOUNDARIES OF NHS AND PRIVATE FUNDED HEALTHCARE DOCUMENT CONTROL TITLE Managing the boundaries of NHS and private funded healthcare AUTHOR Head of Medicines Management VERSION NUMBER
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
More informationCONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION
CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed
More informationPATIENT INFORMATION SHEET KEY FACTS
PATIENT INFORMATION SHEET KEY FACTS Please read this carefully and refer to the full information sheet You are invited to take part in a research study, comparing subcutaneously (injection under skin)
More informationSandwell Community Respiratory Service
Contents Page Community Respiratory Service 2 Service times and locations 3 Oxygen Service 4 Pulmonary Rehabilitation 5 Maintenance Programme 6 Occupational Therapy 7 Dietary support and advice 7 Weatherwise
More informationSpecial Considerations
Special Considerations Women and cart to Treatment What is medication adherence? taking medication exactly the way it is prescribed by the doctor taking the right amount of medication at the right time
More informationMedicines Use Review Supporting Information for Asthma Patients
Medicines Use Review Supporting Information for Asthma Patients What is asthma? Asthma is a chronic inflammatory disorder of the airways. The inflammation causes an associated increase in airway hyper-responsiveness,
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol
PACKAGE LEAFLET: INFORMATION FOR THE USER PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationShared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationInhaler Technique Check
Protocol October 2015 Version 1.3 Table of Contents Service Information... 2 Service objective... 2 Clinical service overview... 2 Documentation... 3 Staff Roles... 3 Facilities to support the program...
More informationCOPD - Education for Patients and Carers Integrated Care Pathway
Patient NHS COPD - Education for Patients and Carers Integrated Care Pathway Date ICP completed:. Is the patient following another Integrated Care Pathway[s].. / If yes, record which other Integrated Care
More informationOpiate Replacement Therapy Prescribing Guidance
Opiate Replacement Therapy Prescribing Guidance Formerly contained within the Methadone Assisted Treatment (MAT) and Buprenorphine Assisted Treatment (BAT) Keyworker Guidelines Approved: May 2017 Version:
More informationYes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
Title: Patient Group Direction for the administration of lidocaine hydrochloride 1% injection as infiltration anaesthesia for insertion/removal of central venous catheters by nurses/radiographers working
More informationGUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Version: 2
SH CP 29 GUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Summary: Guidelines for the use of paliperidone palmitate (Xeplion ) Keywords (minimum of 5): (To assist policy search engine) Target
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationPatient Group Directions. Guidance and information for nurses
Patient Group Directions Guidance and information for nurses Patient Group Directions Guidance and information for nurses Contents Introduction 4 What is a patient group direction (PGD)? 4 When can PGDs
More informationIN-USE PRODUCT SAFETY ASSESSMENT REPORT BENEPALI (ETANERCEPT BIOSIMILAR)
IN-USE PRODUCT SAFETY ASSESSMENT REPORT BENEPALI (ETANERCEPT BIOSIMILAR) SUMMARY OF ASSESSMENT AND ITS FINDINGS BACKGROUND A UK marketing authorisation has been granted to an etanercept biosimilar (SB4,
More informationBETHKIS (Tobramycin Inhalation Solution) Initial U.S. Approval: 1980
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BETHKIS safely and effectively. See full prescribing information for BETHKIS. BETHKIS (Tobramycin
More informationGuidance for Handling Defective Medicinal Products
QUALITY CONTROL WEST MIDLANDS Guidance for Handling Defective Medicinal Products Version 1 March 2006 Wayne Goddard - Laboratory Manager Mitch Phillips - Lead QA Pharmacist, West Midlands SHAs A Guide
More informationLocal Enhanced Service Specification for the Supply of Pharmaceutical Services to Care Homes through Community Pharmacy
Local Enhanced Service Specification for the Supply of Pharmaceutical Services to Care Homes through Community Pharmacy Contents: 1. Introduction and purpose 2. Period of Service 3. Aim of the Service
More informationKeeping patients safe when they transfer between care providers getting the medicines right
PART 1 Keeping patients safe when they transfer between care providers getting the medicines right Good practice guidance for healthcare professions July 2011 Endorsed by: Foreword Taking a medicine is
More informationPrompting, assisting and administration of medication in a care setting: guidance for professionals
Prompting, assisting and administration of medication in a care setting: guidance for professionals Publication date: March 2015 Publication code HCR-0315-092 Page 1 of 6 Background Any care service provision
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More informationGLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST
GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST MEDICINES MANAGEMENT STRATEGY 2006/07 ANNUAL REPORT 1. Aim An annual report on the Trust s Medicines Management Strategy is part of the requirements for Standards
More informationNHS GGC Vitamin D Supplementation Frequently asked Questions
Pharmacy & Prescribing Support Unit NHS GGC Vitamin D Supplementation Frequently asked Questions In February 2012 the Scottish Government issued advice on supplements for groups at risk of vitamin D deficiency.
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
More informationProtocol for the safe administration of iodinated contrast media in diagnostic radiology
Protocol for the safe administration of iodinated contrast media in diagnostic radiology Protocol statement: This protocol applies to all staff within Radiology Departments at Heart of England NHS Foundation
More informationDISEASE MODIFYING THERAPY CARE PATHWAY. Multiple Sclerosis Service
DISEASE MODIFYING THERAPY CARE PATHWAY Multiple Sclerosis Service CONTENTS Disease modifying therapy care pathway ABN guidelines Appendix 1 MS Service DMT Sheet Appendix 2 Who to contact info Appendix
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More information2016 PHARMACY. Benefit Summary Book. RXSUMBK2016 www.fepblue.org
2016 Benefit Summary Book RXSUMBK2016 www.fepblue.org REVIEW THIS SUMMARY BOOKLET TO LEARN HOW TO GET THE MOST FROM YOUR PRESCRIPTION BENEFIT. THIS INCLUDES INFORMATION ABOUT: n Your prescription drug
More informationWard 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home
Ward 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home Contents Page Important contact numbers 1 General information on preparing and administering IV antibiotics
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationChapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.
Chapter 15 Reconstitution and Dosages Measured in Units 1 Objectives Calculating drug dosage problems that first require reconstitution of a powdered drug into a liquid form Using a proportion to solve
More informationSCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE
SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE 1 P a g e The following Operational Guidance Manual has been prepared with input from both community and prison addictions specialists
More informationJune 2010 Pharmacy Professional
f e at u r e s p e c i a l s Dealing with specials Responding to members requests the Society presents practical guidance for pharmacists on professional responsibilities when dealing with the supply of
More informationSupport to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence
Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence SUMMARY 1) Derbyshire Substance misuse service provides Psycho-social treatment interventions for ALL
More informationGood practice for drug calculations
Good practice for drug calculations A step-by-step guide for nurses, doctors and all other healthcare professionals Pharmacyservices 7048 Drug Cal Guide A6 Update_AW.indd 1 22/07/2014 09:55 2 Contents
More informationHOSPITAL PHARMACY PRACTICE IN THE UK AND THE RESPONSIBLE PHARMACIST REQUIREMENTS
HOSPITAL PHARMACY PRACTICE IN THE UK AND THE RESPONSIBLE PHARMACIST REQUIREMENTS ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN AND THE PHARMACEUTICAL SOCIETY OF NORTHERN IRELAND STATUS OF THIS DOCUMENT
More informationThe Medicines Policy. Chapter 2: Standards of Practice PRESCRIBING
Chapter 2: Standards of Practice PRESCRIBING V2.1 Date: January 2015 CHAPTER 2 Table of Contents 6. Standards and Practice... 3 6.1. Prescribing... 3 6.1.1 Patient-Centred Prescribing... 3 6.1.2 Prescription
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationGUIDELINE FOR ADMINISTRATION OF FENTANYL FOR PAIN RELIEF IN LABOUR
GUIDELINE FOR ADMINISTRATION OF FENTANYL FOR PAIN RELIEF IN LABOUR INTRODUCTION Intravenous (IV) Fentanyl is a good option for pain management during labour and should be administered in a safe and competent
More information